Evidence map›Paper›PMID 39540692›Full record

ArticleOrganic letters2024

β-d-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development.

Jih Ru Hwu, Avijit Panja, Shwu-Chen Tsay, Wen-Chieh Huang, Shu-Yu Lin, Chen-Sheng Yeh, Wu-Chou Su, Li-Xing Yang, Dar-Bin Shieh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Organic letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jih Ru HwuDepartment of Chemistry & Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300, Taiwan.ORCID 0000-0002-9225-8484
Avijit PanjaDepartment of Chemistry & Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300, Taiwan.ORCID 0000-0002-1336-8547
Shwu-Chen TsayDepartment of Chemistry & Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300, Taiwan.
Wen-Chieh HuangDepartment of Chemistry & Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300, Taiwan.
Shu-Yu LinInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Miaoli County 350401, Taiwan.
Chen-Sheng YehDepartment of Chemistry, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0001-5102-3884
Wu-Chou SuDepartment of Internal Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Li-Xing YangDepartment of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Dar-Bin ShiehDepartment of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan 701, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and carbonate groups as linking joints, a phosphodiester moiety as an enzyme recognition site, and lenalidomide and paclitaxel as the constituent drugs. The codrug synthesis involves seven steps with a 33% overall yield. The target codrug increases its water solubility 685 times versus paclitaxel.

Indexed as

PaclitaxelCarbamatesDrug DesignMolecular StructureSolubilityThalidomideCarbamatesPaclitaxelThalidomide

Identifiers

PMID39540692
PMCPMC11590094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.